ストックスクリーナーアプリを入手
2.50
5.30%
-0.14
アフターアワーズ：
2.50
前日終値:
$2.64
開ける：
$2.51
24時間の取引高:
3,064
Relative Volume:
0.19
時価総額：
$5.73M
収益：
$3.19M
当期純損益:
$-2.23M
株価収益率:
-2.0337
EPS:
-1.2293
ネットキャッシュフロー:
$-1.82M
1週間 パフォーマンス:
-11.03%
1か月 パフォーマンス:
-15.11%
6か月 パフォーマンス:
-1.96%
1年 パフォーマンス:
-30.62%
1日の値動き範囲:
$2.50
$2.5677
1週間の範囲:
$2.4501
$2.9872
52週間の値動き範囲:
$1.90
$13.93
Xenetic Biosciences Inc Stock (XBIO) Company Profile
名前
Xenetic Biosciences Inc
セクター
電話
781-778-7720
住所
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
2.50 | 6.05M | 3.19M | -2.23M | -1.82M | -1.2293 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-01-08 | 開始されました | Maxim Group | Buy |
Xenetic Biosciences Inc (XBIO) 最新ニュース
Xenetic Biosciences Inc (XBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XBIO|Xenetic Biosciences Inc|Price:2.640|Chg%:-0.085 - TradingKey
Xenetic Biosciences Inc (XBIO) Cash Flow - TradingKey
Xenetic Biosciences Inc (XBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Number of shareholders of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Price to book forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Enterprise value to revenue forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Price to earnings forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Enterprise value to EBITDA forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Price to sales forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Enterprise value to EBIT forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Xenetic Biosciences (XBIO) Surges 6.14% as Stock Tests Key Resistance at $3.09Large Cap Trends - dars.gov.et
XBIOXenetic Biosciences Inc Latest SEC Filings - Finviz
Xenetic Biosciences, Inc. Actuals & Estimates (NASDAQ:XBIO) - TradingView
Xenetic Biosciences Inc (XBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Xenetic Biosciences Inc (XBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Xenetic Biosciences Inc (XBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xenetic Biosciences Inc (XBIO) Institutional Confidence - TradingKey
Xenetic Biosciences Inc (XBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Xenetic Biosciences Inc (XBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xenetic Biosciences Inc (XBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xenetic Biosciences (XBIO) Gains 6.7% – Bullish Breakout Within Tight RangeBreakout Stock Alerts - newsline.com
Xenetic Biosciences (XBIO) Holds Tight Range Near $3.10 with Minimal MovementFibonacci Time Zone - dars.gov.et
XBIO Q2 2025 Earnings: EPS Surpasses Estimates Despite No RevenueLong-Term Guidance - dars.gov.et
XBIO Q2 2025 Earnings: Narrower Loss Beats Estimates, Yet Stock Slips on No Revenue ProgressAnalyst Coverage Count - dars.gov.et
Xenetic Biosciences (XBIO) Secures Approval for Clinical Study i - GuruFocus
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma - ACCESS Newswire
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates - MSN
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival - BioSpace
Xenetic presents preclinical data on DNase I with CAR-T therapy - Investing.com Nigeria
Xenetic (XBIO) Reveals Promising Preclinical Results for CAR-T Therapy - GuruFocus
Xenetic presents preclinical data on DNase I with CAR-T therapy By Investing.com - Investing.com South Africa
Xenetic Biosciences, Inc.: Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival - FinanzNachrichten.de
After CAR-T failure, DNase I tied to tumor decline in pediatric lymphoma case - Stock Titan
Michael Liu and MJL Manager LLC report stakes in Xenetic Biosciences (NASDAQ: XBIO) - Stock Titan
XBIO Q2 2025 Earnings: Narrowed Loss Exceeds Expectations as Pipeline AdvancesEarnings Risk Report - dars.gov.et
Xenetic Biosciences (XBIO) Edges Lower Amid Tight Trading RangeKAMA Signal - dars.gov.et
Xenetic Biosciences (XBIO) Modestly Advances as Biotech Stock Tests Key Resistance ZoneVolume Climax - The Legal Advocate
Xenetic Biosciences Q2 2025 Earnings: Narrowed Loss Exceeds Expectations Amid Oncology Pipeline Progress - The Legal Advocate
Xenetic Biosciences (XBIO) Bounces 3.03%, Holding Above Key SupportBreakout Confirmation - newsline.com
Xenetic Biosciences Q2 2025 Earnings: Narrowed Loss Beats Estimates as Pipeline AdvancesPre-Earnings Drift - Newser
Xenetic Biosciences Shares Edge Down Ahead of ASCO Update - Bez Kabli
XBIO Stock Price, Quote & Chart | XENETIC BIOSCIENCES INC (NASDAQ:XBIO) - ChartMill
Xenetic Biosciences (XBIO) Q2 2025 Earnings Roar: $-0.45 EPS Tops Street ViewCommunity Momentum Stocks - Newser
Xenetic Biosciences (XBIO) Declines -3.75% Amid Market Weakness 2026-05-18Community Watchlist Picks - Newser
Contact Us – Inside INdiana BusinessXenetic Biosciences, Inc.Common Stock (Nasdaq:XBIO) Stock Quote - FinancialContent
Renaissance Holdings Reports 137,440 XBIO Shares (NASDAQ: XBIO) - Stock Titan
Xenetic (XBIO) Reports Strong Q1 Revenue Growth - GuruFocus
Xenetic Virtually Unchanged - Baystreet.ca
Xenetic Biosciences Reports Q1 2026 Results: Advances DNase Oncology Platform, Grows Royalty Revenue, and Strengthens Financial Position - Minichart
Xenetic Biosciences Inc (XBIO) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):